SalioGen Therapeutics

SalioGen Therapeutics is a biotechnology company based in Lexington, Massachusetts. The company employs 54 people and generates $20 million in annual revenue. SalioGen is focused on developing a new category of genetic medicine called Gene Coding. This technology works by adding a new genomic code to control the functions of genes. Their initial focus is on developing treatments for inherited disorders, aiming for therapies that are durable, safe, and accessible to a wide range of patients. The company's approach is guided by their Exact DNA Integration Technology (EDIT) platform. This genome engineering technology utilizes proprietary mammal-derived enzymes known as Saliogase. EDIT offers broad applicability, non-viral delivery capabilities for genes of any size, and significant manufacturing advantages, potentially revolutionizing the treatment of inherited disorders and beyond. For more information about SalioGen Therapeutics, visit their website at saliogen.com.